Dinaciclib for the treatment of breast cancer

Bibliography

• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24(11):1770-83
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007;17(1):60-5
   PubMed Web of Science ®Google Scholar
• Morgan DO. Principles of CDK regulation. Nature 1995;374(6518):131-4
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13(12):1501-12
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9(3):153-66
   PubMed Web of Science ®Google Scholar
• Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002;190(2):160-9
   PubMed Web of Science ®Google Scholar
• Dhariwala FA, Rajadhyaksha MS. An unusual member of the Cdk family: cdk5. Cell Mol Neurobiol 2008;28(3):351-69
   PubMed Web of Science ®Google Scholar
• Marzuka-Alcala A, Gabree MJ, Tsao H. Melanoma susceptibility genes and risk assessment. Methods Mol Biol 2014;1102:381-93
   PubMedGoogle Scholar
• Abdullah C, Wang X, Becker D. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell cycle 2011;10(6):977-88
   PubMed Web of Science ®Google Scholar
• Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell cycle 2012;11(14):2756-61
   PubMed Web of Science ®Google Scholar
• Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004;18(4):747-55
   PubMed Web of Science ®Google Scholar
• McMillin DW, Delmore J, Negri J, et al. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol 2011;152(4):420-32
   PubMed Web of Science ®Google Scholar
• Quereda V, Malumbres M. Cell cycle control of pituitary development and disease. J Mol Endocrinol 2009;42(2):75-86
   PubMed Web of Science ®Google Scholar
• Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602(1):73-87
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Maurer M. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms. Curr Pharm Des 2011;17(3):256-71
   PubMed Web of Science ®Google Scholar
• Johnson N, Shapiro GI. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 2010;14(11):1199-212
   PubMed Web of Science ®Google Scholar
• Liebl J, Krystof V, Vereb G, et al. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases. Angiogenesis 2011;14(3):281-91
   PubMed Web of Science ®Google Scholar
• Davies TG, Pratt DJ, Endicott JA, et al. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol Ther 2002;93(2-3):125-33
   PubMed Web of Science ®Google Scholar
• Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009;113(12):2637-45
   PubMed Web of Science ®Google Scholar
• Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27(35):6012-18
   PubMed Web of Science ®Google Scholar
• Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002;20(19):4074-82
   PubMed Web of Science ®Google Scholar
• Tan AR, Swain SM. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin Oncol 2002;29(3 Suppl 11):77-85
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96(1):29-37
   PubMed Web of Science ®Google Scholar
• Dickson MA, Shah MA, Rathkopf D, et al. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol 2010;66(6):1113-21
   PubMed Web of Science ®Google Scholar
• Fekrazad HM, Verschraegen CF, Royce M, et al. A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. Am J Clin Oncol 2010;33(4):393-7
   PubMed Web of Science ®Google Scholar
• Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011;137(10):1409-18
   PubMed Web of Science ®Google Scholar
• Rathkopf D, Dickson MA, Feldman DR, et al. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res 2009;15(23):7405-11
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Cancer Res 2012;72(24 Suppl):abstract S1-6
   Google Scholar
• Mohapatra S, Chu B, Zhao X, et al. Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors. Int J Biochem Cell Biol 2009;41(3):595-602
   PubMed Web of Science ®Google Scholar
• Boss DS, Schwartz GK, Middleton MR, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol 2010;21(4):884-94
   PubMed Web of Science ®Google Scholar
• Abate AA, Pentimalli F, Esposito L, Giordano A. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview. Expert Opin Investig Drugs 2013;22(7):895-906
   PubMed Web of Science ®Google Scholar
• Bruyere C, Meijer L. Targeting cyclin-dependent kinases in anti-neoplastic therapy. Curr Opin Cell Biol 2013;25(6):772-9
   PubMed Web of Science ®Google Scholar
• Nair BC, Vallabhaneni S, Tekmal RR, Vadlamudi RK. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res 2011;13(3):R80
   PubMedGoogle Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18(2):568-76
   PubMed Web of Science ®Google Scholar
• A study of palbociclib (PD-0332991) + letrozole vs. letrozole for 1st Line. treatment of postmenopausal women with ER+/HER2- advanced breast cancer (PALOMA-2). 2014. Available from: http://clinicaltrials.gov/show/NCT01740427
   Google Scholar
• Phase III study of palbociclib (PD-0332991) in combination with exemestane versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitors (PEARL). 2014. Available from: http://clinicaltrials.gov/show/NCT02028507
   Google Scholar
• A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). 2014. Available from: http://clinicaltrials.gov/show/NCT01864746
   Google Scholar
• Phase 1b study of PD-0332991 in combination with T-DM1(Trastuzumab-DM1) in the treatment of patients with advanced HER2-positive breast cancer. 2014. Available from: http://www.utsouthwestern.edu/research/fact/detail.html?studyid=STU%20042013-042
   Google Scholar
• PD0332991/Paclitaxel in advanced breast cancer. 2014. Available from: http://clinicaltrials.gov/show/NCT01320592
   Google Scholar
• Nagaria TS, Williams JL, Leduc C, et al. Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems. Neoplasia 2013;15(8):939-51
   PubMed Web of Science ®Google Scholar
• Mitchell C, Yacoub A, Hossein H, et al. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 2010;10(9):903-17
   PubMed Web of Science ®Google Scholar
• Fornier MN, Rathkopf D, Shah M, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007;13(19):5841-6
   PubMed Web of Science ®Google Scholar
• Docetaxel and flavopiridol in treating patients with locally advanced or metastatic breast cancer. 2014. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00020332?term=metastatic+breast+cancer&lup_s=05%2F31%2F2013&lup_d=30
   Google Scholar
• Flavopiridol plus cisplatin or carboplatin in treating patients with advanced solid tumors. 2014. Available from: http://www.rxwiki.com/clinical-trial/flavopiridol-plus-cisplatin-or-carboplatin-treating-patients-advanced-solid-tumors
   Google Scholar
• Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9(8):2344-53
   PubMed Web of Science ®Google Scholar
• Feldmann G, Mishra A, Bisht S, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 2011;12(7):598-609
   PubMed Web of Science ®Google Scholar
• Fu W, Ma L, Chu B, et al. The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther 2011;10(6):1018-27
   PubMed Web of Science ®Google Scholar
• Martin MP, Olesen SH, Georg GI, Schonbrunn E. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol 2013;8(11):2360-5
   PubMed Web of Science ®Google Scholar
• Nguyen TK, Grant S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol Cancer Ther 2014;13(3):662-74
   PubMed Web of Science ®Google Scholar
• Nemunaitis JJ, Small KA, Kirschmeier P, et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 2013;11:259
   PubMed Web of Science ®Google Scholar
• Mita MM MA, Moseley J, Poon J, et al. A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: final results. J Clin Oncol 2011;29(Suppl):abstract 3080
   Google Scholar
• Dinaciclib and Akt inhibitor MK2206 in treating patients with pancreatic cancer that cannot be removed by surgery. 2014. Available from: http://clinicaltrials.gov/show/NCT01783171
   Google Scholar
• Dinaciclib in treating patients with stage III-IV melanoma. 2014. Available from: http://clinicaltrials.gov/show/NCT01026324
   Google Scholar
• Dinaciclib in treating patients with stage IV melanoma. 2014. Available from: http://www.cancer.gov/clinicaltrials/search/view?cdrid=647155&version=HealthProfessional
   Google Scholar
• Dinaciclib, bortezomib, and dexamethasone in treating patients with relapsed multiple myeloma. 2014. Available from: clinicaltrials.gov/show/NCT01711528
   Google Scholar
• Ofatumumab and dinaciclib in treating patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, or B-cell prolymphocytic leukemia. 2014. Available from: clinicaltrials.gov/show/NCT01515176
   Google Scholar
• A Phase 3 study comparing dinaciclib versus ofatumumab in patients with refractory chronic lymphocytic leukemia (P07714 AM2). 2014. Available from: http://clinicaltrials.gov/show/NCT01580228
   Google Scholar
• Phase 1 weekly dosing of SCH 727965 in patients with advanced cancer (study P04629AM6). 2014. Available from: http://clinicaltrials.gov/show/NCT00871663
   Google Scholar
• Horiuchi D, Kusdra L, Huskey NE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012;209(4):679-96
   PubMed Web of Science ®Google Scholar
• Dinaciclib and epirubicin hydrochloride in treating patients with metastatic triple-negative breast cancer. 2014. Available from: http://clinicaltrials.gov/show/NCT01624441
   Google Scholar
• Phase I/Ib dose-escalation of dinaciclib with weekly paclitaxel for advanced solid tumor malignancies & assessment of MYC oncogene overexpression. 2014. Available from: http://clinicaltrials.gov/show/NCT01676753
   Google Scholar
• Veliparib and dinaciclib with or without carboplatin in treating patients with advanced solid tumors. 2014. Available from: http://clinicaltrials.gov/show/NCT01434316
   Google Scholar
• Mita M, Joy AA, Mita A, et al. Randomized Phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer 2014;14(3):169-76
   PubMed Web of Science ®Google Scholar
• Gojo I, Sadowska M, Walker A, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol 2013;72(4):897-908
   PubMed Web of Science ®Google Scholar
• Booher R, Strack P, Zawel L, et al. Mcl-1 dependency is a predictive biomarker for apoptotic induction by short-term dinaciclib (SCH 727965) treatment. Cancer Res 2012;72(8 Suppl):abstract nr 3063
   Google Scholar
• Finn R, Crown J, Lang I, et al. Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) [abstract nr CT-101]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5 – 9 April 2014; San Diego, CA. Philadelphia (PA). AACR 2014
   Google Scholar
• Slamon D, Hurvitz S, Applebaum S, et al. Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER positive, HER2-negative breast cancer. J Clin Oncol 2010;28:abstract 3060
   Google Scholar
• Desai BM, Villanueva J, Nguyen TT, et al. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One 2013;8(3):e59588
   PubMed Web of Science ®Google Scholar
• Johnson AJ, Yeh YY, Smith LL, et al. The novel cyclin-dependent kinase inhibitor dinaciclib (sch727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 2012;26(12):2554-7
   PubMed Web of Science ®Google Scholar
• Gorlick R, Kolb EA, Houghton PJ, et al. Initial testing (stage 1) of the cyclin dependent kinase inhibitor sch 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;59(7):1266-74
   PubMed Web of Science ®Google Scholar
• Stephenson JJ, Nemunaitis J, Joy AA, et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (mk-7965) versus erlotinib in patients with non-small cell lung cancer. Lung cancer 2014;83(2):219-23
   PubMed Web of Science ®Google Scholar